TGF-β Neutralization Enhances AngII-Induced Aortic Rupture and Aneurysm in Both Thoracic and Abdominal Regions.
AngII and TGF-β interact in development of thoracic and abdominal aortic diseases, although there are many facets of this interaction that have not been clearly defined. The aim of the present study was to determine the effects of TGF-β neutralization on AngII induced-aortic pathologies. Male C57BL/6J mice were administered with either a rabbit or mouse TGF-β neutralizing antibody and then infused with AngII. The rabbit TGF-β antibody modestly reduced serum TGF-β concentrations, with no significant enhancements to AngII-induced aneurysm or rupture. Administration of this rabbit TGF-β antibody in mice led to high serum titers against rabbit IgG that may have attenuated the neutralization. In contrast, a mouse TGF-β antibody (1D11) significantly increased rupture in both the ascending and suprarenal aortic regions, but only at doses that markedly decreased serum TGF-β concentrations. High doses of 1D11 antibody significantly increased AngII-induced ascending and suprarenal aortic dilatation. To determine whether TGF-β neutralization had effects in mice previously infused with AngII, the 1D11 antibody was injected into mice that had been infused with AngII for 28 days and were observed during continued infusion for a further 28 days. Despite near ablations of serum TGF-β concentrations, the mouse TGF-β antibody had no effect on aortic rupture or dimensions in either ascending or suprarenal region. These data provide further evidence that AngII-induced aortic rupture is enhanced greatly by TGF-β neutralization when initiated before pathogenesis.
Laboratory of Cardiovascular Disease, Department of Cardiology, Taizhou Hospital, Wenzhou Medical University, Zhejiang, China.|Saha Cardiovascular Research Center, University of Kentucky, Lexington, Kentucky, United States of America.
Xiaofeng
X
Chen
Saha Cardiovascular Research Center, University of Kentucky, Lexington, Kentucky, United States of America.
Debra L
DL
Rateri
Saha Cardiovascular Research Center, University of Kentucky, Lexington, Kentucky, United States of America.
Deborah A
DA
Howatt
Saha Cardiovascular Research Center, University of Kentucky, Lexington, Kentucky, United States of America.
Anju
A
Balakrishnan
Saha Cardiovascular Research Center, University of Kentucky, Lexington, Kentucky, United States of America.
Jessica J
JJ
Moorleghen
Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, Kentucky, United States of America.
Lisa A
LA
Cassis
Saha Cardiovascular Research Center, University of Kentucky, Lexington, Kentucky, United States of America.|Department of Physiology, University of Kentucky, Lexington, Kentucky, United States of America.
Alan
A
Daugherty
D000804:Angiotensin II / Q000494:pharmacology*; D000818:Animals; D017544:Aortic Aneurysm, Abdominal / Q000209:etiology*; D017545:Aortic Aneurysm, Thoracic / Q000209:etiology*; D001019:Aortic Rupture / Q000139:chemically induced*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D016212:Transforming Growth Factor beta / Q000494:pharmacology*
D016212:Transforming Growth Factor beta; D000804:Angiotensin II